Get the Stockscreener App
161.06
0.85%
-1.38
After Hours:
161.06
Krystal Biotech Inc stock is traded at $161.06, with a volume of 142.40K.
It is down -0.85% in the last 24 hours and up +3.37% over the past month.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
See More
Previous Close:
$162.44
Open:
$162.86
24h Volume:
142.40K
Relative Volume:
0.54
Market Cap:
$4.63B
Revenue:
$241.52M
Net Income/Loss:
$52.37M
P/E Ratio:
90.48
EPS:
1.78
Net Cash Flow:
$58.06M
1W Performance:
+3.20%
1M Performance:
+3.37%
6M Performance:
-9.83%
1Y Performance:
+40.33%
1-Day Range:
$159.91
$162.96
1-Week Range:
$154.37
$165.51
52-Week Range:
$107.50
$219.34
Krystal Biotech Inc Stock (KRYS) Company Profile
Name
Krystal Biotech Inc
Sector
Industry
Phone
(412) 586-5830
Address
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
161.06 | 4.63B | 241.52M | 52.37M | 58.06M | 1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-12-23 | Initiated | Citigroup | Buy |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Feb-28-23 | Upgrade | Goldman | Neutral → Buy |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-18-22 | Initiated | BofA Securities | Buy |
| Jul-20-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Jun-04-20 | Initiated | Evercore ISI | Outperform |
| Sep-24-19 | Initiated | Goldman | Neutral |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-24-19 | Reiterated | H.C. Wainwright | Buy |
| May-30-19 | Initiated | Guggenheim | Buy |
| Sep-11-18 | Initiated | Cantor Fitzgerald | Overweight |
View All
Krystal Biotech Inc Stock (KRYS) Latest News
Krystal Biotech Schedules Critical Year-End Financial Results: Key Details for Biotech Investors - StockTitan
Blue Trust Inc. Acquires 433 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
STATE STREET CORP Reduces Stake in Krystal Biotech Inc - GuruFocus.com
Jennison Associates LLC Lowers Stake in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
1,400 Shares in Krystal Biotech, Inc. (NASDAQ:KRYS) Acquired by Pacer Advisors Inc. - Defense World
Krystal Biotech, Inc. (NASDAQ:KRYS) Sees Significant Decline in Short Interest - MarketBeat
Janney Montgomery Scott LLC Increases Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Analysts Set Krystal Biotech, Inc. (NASDAQ:KRYS) Target Price at $206.67 - Defense World
Crossmark Global Holdings Inc. Buys 121 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
When (KRYS) Moves Investors should Listen - Stock Traders Daily
Analysts Set Krystal Biotech, Inc. (NASDAQ:KRYS) PT at $206.67 - MarketBeat
Is the Options Market Predicting a Spike in Krystal Biotech (KRYS) Stock? - MSN
US Growth Companies With High Insider Ownership In January 2025 - Simply Wall St
High Growth Tech Stocks to Watch in January 2025 - Simply Wall St
(KRYS)Analyzing Krystal Biotech's Short Interest - Benzinga
Krystal Biotech, Inc. (NASDAQ:KRYS) Short Interest Down 8.9% in December - Defense World
Short Interest in Krystal Biotech, Inc. (NASDAQ:KRYS) Drops By 8.9% - MarketBeat
GAMMA Investing LLC Lowers Stake in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Jeune Aesthetics names new CFO ahead of Phase 2 trials By Investing.com - Investing.com Canada
Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer - GlobeNewswire
Jeune Aesthetics names new CFO ahead of Phase 2 trials - Investing.com
Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer - GlobeNewswire Inc.
Krystal Biotech Becomes Oversold (KRYS) - Nasdaq
JPMorgan Chase & Co. Has $23.28 Million Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
JPMorgan Chase & Co. Has $23.28 Million Stake in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
City Therapeutics Appoints Andy Orth as Chief Executive Officer - Marketscreener.com
Here's How Much $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today - Benzinga
(KRYS) Proactive Strategies - Stock Traders Daily
Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Krystal Biotech: Blockbuster Ambitions For Topical Gene Therapy (NASDAQ:KRYS) - Seeking Alpha
Principal Financial Group Inc. Sells 3,743 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
(KRYS) Technical Pivots with Risk Controls - Stock Traders Daily
3 US Growth Stocks With Insider Ownership Expecting Up To 85% Earnings Growth - Simply Wall St
Krystal Biotech, Inc. (NASDAQ:KRYS) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? - Yahoo Finance
Avalon GloboCare (NASDAQ:ALBT) vs. Krystal Biotech (NASDAQ:KRYS) Head-To-Head Analysis - Defense World
Krystal Biotech (KRYS) – Research Analysts’ Weekly Ratings Changes - Defense World
Chardan Capital Reaffirms “Buy” Rating for Krystal Biotech (NASDAQ:KRYS) - Defense World
Krystal Biotech reports success with inhalable lung cancer drug in early-stage trial - Mugglehead
KRYS Reports Upbeat Initial Data From Lung Cancer Study Of KB707 - Barchart
KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707 - Yahoo Finance
Geode Capital Management LLC Purchases 11,411 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer - Marketscreener.com
Wellington Management Group LLP Buys 1,660 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech reports promising lung cancer trial results By Investing.com - Investing.com Australia
Krystal Biotech Reports Positive Results for KYANITE-1 Study - TipRanks
Krystal Biotech (NASDAQ:KRYS) Given "Buy" Rating at Chardan Capital - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Shares Gap UpWhat's Next? - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Receives "Buy" Rating from HC Wainwright - MarketBeat
Krystal Biotech reports promising lung cancer trial results - Investing.com
Krystal Biotech Inc Stock (KRYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):